137 related articles for article (PubMed ID: 18292947)
1. Polysaccharopeptide enhances the anticancer activity of doxorubicin and etoposide on human breast cancer cells ZR-75-30.
Wan JM; Sit WH; Louie JC
Int J Oncol; 2008 Mar; 32(3):689-99. PubMed ID: 18292947
[TBL] [Abstract][Full Text] [Related]
2. Induction of S phase cell arrest and caspase activation by polysaccharide peptide isolated from Coriolus versicolor enhanced the cell cycle dependent activity and apoptotic cell death of doxorubicin and etoposide, but not cytarabine in HL-60 cells.
Hui KP; Sit WH; Wan JM
Oncol Rep; 2005 Jul; 14(1):145-55. PubMed ID: 15944782
[TBL] [Abstract][Full Text] [Related]
3. The cell death process of the anticancer agent polysaccharide-peptide (PSP) in human promyelocytic leukemic HL-60 cells.
Yang X; Sit WH; Chan DK; Wan JM
Oncol Rep; 2005 Jun; 13(6):1201-10. PubMed ID: 15870943
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
[TBL] [Abstract][Full Text] [Related]
6. Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol.
Thomadaki H; Scorilas A
Biol Chem; 2008 Nov; 389(11):1427-34. PubMed ID: 18783338
[TBL] [Abstract][Full Text] [Related]
7. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc.
Bidwell GL; Raucher D
Biochem Pharmacol; 2006 Jan; 71(3):248-56. PubMed ID: 16316634
[TBL] [Abstract][Full Text] [Related]
9. Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Thomadaki H; Mavridis K; Talieri M; Scorilas A
Thromb Haemost; 2009 Feb; 101(2):373-80. PubMed ID: 19190824
[TBL] [Abstract][Full Text] [Related]
10. Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells.
Ravizza R; Gariboldi MB; Molteni R; Monti E
Oncol Rep; 2008 Sep; 20(3):625-30. PubMed ID: 18695915
[TBL] [Abstract][Full Text] [Related]
11. Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction.
Liu XH; Zheng XF; Wang YL
Chin Med J (Engl); 2009 Jul; 122(14):1681-5. PubMed ID: 19719971
[TBL] [Abstract][Full Text] [Related]
12. 3-D tumor model for in vitro evaluation of anticancer drugs.
Horning JL; Sahoo SK; Vijayaraghavalu S; Dimitrijevic S; Vasir JK; Jain TK; Panda AK; Labhasetwar V
Mol Pharm; 2008; 5(5):849-62. PubMed ID: 18680382
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
[TBL] [Abstract][Full Text] [Related]
14. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
15. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231.
Aroui S; Brahim S; De Waard M; Bréard J; Kenani A
Cancer Lett; 2009 Nov; 285(1):28-38. PubMed ID: 19523755
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models.
Hou W; Chen L; Yang G; Zhou H; Jiang Q; Zhong Z; Hu J; Chen X; Wang X; Yuan Y; Tang M; Wen J; Wei Y
Phytother Res; 2008 Aug; 22(8):1125-32. PubMed ID: 18570244
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.
Howell SB; Hom D; Sanga R; Vick JS; Abramson IS
Cancer Res; 1989 Jun; 49(12):3178-83. PubMed ID: 2720673
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Shiozawa K; Nakanishi T; Tan M; Fang HB; Wang WC; Edelman MJ; Carlton D; Gojo I; Sausville EA; Ross DD
Clin Cancer Res; 2009 Mar; 15(5):1698-707. PubMed ID: 19223502
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells.
Choi EJ; Bae SM; Ahn WS
Arch Pharm Res; 2008 Oct; 31(10):1281-5. PubMed ID: 18958418
[TBL] [Abstract][Full Text] [Related]
20. Coenzyme Q0 induces apoptosis and modulates the cell cycle in estrogen receptor negative breast cancer cells.
Somers-Edgar TJ; Rosengren RJ
Anticancer Drugs; 2009 Jan; 20(1):33-40. PubMed ID: 18830129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
